ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hospital

Bigger, More Expensive Healthcare Practices Not Necessarily Better

Ronnie Cohen  |  

(Reuters Health)—You might not get what you pay for when it comes to healthcare, a new study hints. A report in Health Affairs on May 2 found little association between how much physician practices charged and patients’ perceptions of their quality of care.1 “We’re asking consumers to make a lot of decisions about healthcare purchasing…

Cracking, Popping Joints May Foretell Arthritis

Carolyn Crist  |  

(Reuters Health)—Grating, cracking or popping sounds around joints may predict future arthritis, especially in the knees, according to a recent U.S. study. Among thousands of people with no knee pain who were followed for three years, one quarter had noisy knees yet they made up three quarters of the cases of symptomatic knee arthritis that…

Pricey Arthritis Drug Effective in Small Fraction of Ulcerative Colitis Cases

Gene Emery  |  

NEW YORK (Reuters Health)—Pfizer’s expensive arthritis drug tofacitinib has been shown to produce a remission in nearly 1 in 5 patients with moderate to severe ulcerative colitis, but long-term remission persists in fewer than half of those cases. In a series of studies published in the May 4 New England Journal of Medicine, researchers reported…

Institute for Clinical Economic Review Final Report on RA Treatments

  |  

On April 7, 2017, the Institute for Clinical and Economic Review (ICER) published its final report, titled, Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value.1 The stated objective of the report was to assess the comparative clinical effectiveness of the targeted immune modulators (TIMs) used to treat patients with moderate to severe active rheumatoid…

Tofacitinib Treatment May Improve Nail Psoriasis

Rita Buckley  |  

NEW YORK (Reuters Health)—The oral Janus kinase (JAK) inhibitor tofacitinib appears to improve moderate to severe nail psoriasis, according to a new study. “Nails are hard to treat in psoriasis and we need better treatments,” says Dr. Luis Garza, a dermatologist at Johns Hopkins School of Medicine in Baltimore, who was not involved in the research….

Studies Highlight Risk of Damage from Lupus Treatments

  |  

WASHINGTON, D.C.—Conference goers who braved the final day of the 2016 ACR/ARHP Annual Meeting were awarded for their stamina by learning about issues relating to the damage caused by systemic lupus erythematosus (SLE) during the session Systemic Lupus Erythematosus—Clinical Aspects and Treatment V: Damage and Morbidity. Minimizing Damage: Early Use of GC-Sparing Strategies Jayne Little,…